Kiora Pharmaceuticals Inc
KPRXNasdaqCIK 1372514HealthcareFiscal year ends Dec 31
Reports and events: 266 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2907:03 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000088 |
| 2026-09-0807:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000079 |
| 2026-08-1907:01 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000077 |
| 2026-08-0707:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-26-000075 |
| 2026-08-0707:02 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001372514-26-000074 |
| 2026-06-1807:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000063 |
| 2026-06-1118:39 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001372514-26-000059 |
| 2026-05-0807:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-26-000048 |
| 2026-05-0807:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001372514-26-000047 |
| 2026-04-3017:11 ET | DEF 14A | Proxy statementPeriod 2026-04-16 | 0001372514-26-000040 |
| 2026-04-0707:01 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000036 |
| 2026-04-0216:44 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000028 |
| 2026-03-2507:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-26-000025 |
| 2026-03-2507:01 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001372514-26-000024 |
| 2025-11-0706:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-25-000079 |
| 2025-11-0706:01 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001372514-25-000078 |
| 2025-08-1318:00 ET | 8-K | 7.01 Regulation FD disclosure | 0001372514-25-000068 |
| 2025-08-0807:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-25-000064 |
| 2025-08-0807:01 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001372514-25-000061 |
| 2025-06-0414:34 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001372514-25-000053 |
| 2025-06-0307:00 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-25-000050 |
| 2025-05-0907:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-25-000045 |
| 2025-05-0906:59 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001372514-25-000044 |
| 2025-04-3010:00 ET | DEF 14A | Proxy statementPeriod 2025-04-16 | 0001372514-25-000038 |
| 2025-03-2507:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-25-000014 |
| 2025-03-2506:55 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001372514-25-000012 |
| 2025-01-1517:22 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001372514-25-000003 |
| 2024-11-0807:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-24-000121 |
| 2024-11-0807:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001372514-24-000120 |
| 2024-10-2907:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-24-000117 |
| 2024-08-0907:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-24-000105 |
| 2024-08-0907:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001372514-24-000104 |
| 2024-07-3007:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001372514-24-000099 |
| 2024-07-0107:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001372514-24-000068 |
| 2024-06-0707:02 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001372514-24-000057 |
| 2024-05-1007:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-24-000054 |
| 2024-05-1007:00 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001372514-24-000053 |
| 2024-05-0317:56 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001372514-24-000039 |
| 2024-03-2516:32 ET | DEF 14A | Proxy statementPeriod 2024-05-01 | 0001372514-24-000030 |
| 2024-03-2507:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-24-000027 |
| 2024-03-2507:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001372514-24-000026 |
| 2024-02-1217:23 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-24-000013 |
| 2024-02-0107:01 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-24-000010 |
| 2024-01-3117:14 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-24-000007 |
| 2024-01-1617:16 ET | 8-K | 3.01 Delisting notice | 0001372514-24-000002 |
| 2023-11-0907:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-23-000160 |
| 2023-11-0907:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-23-000159 |
| 2023-11-0907:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001372514-23-000158 |
| 2023-11-0606:05 ET | 8-K | 9.01 Financial statements and exhibits | 0001372514-23-000154 |
| 2023-09-2819:06 ET | 8-K | 5.07 Shareholder vote results | 0001372514-23-000132 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 07:04 ET. Listed shows no prices and gives no investment advice.